Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacturing, marketing, sale, and distribution of generic and brand pharmaceutical products focused on urology and womens health in the United States, western Europe, Canada, Australasia, South America, and South Africa. The company offers its products for therapeutic categories, such as central nervous system, hormones and synthetic substitutes, cardiovascular, anti-infective agents, and urology. It operates in three segments: Global Generics, Global Brands, and Distribution. The Global Generics segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties brand products. This segment offers various dosage forms, such as oral solids, transdermals, injectables, inhalation products, and transmucosals for indications, including pregnancy prevention, pain management, depression, hypertension, and smoking cessation. The Global Brands segment promotes and co-promotes Rapaflo, Gelnique, Trelstar, Crinone, ella, INFeD, AndroGel, and Femring branded products; and markets its products through sales professionals. It also sells various non-promoted products. The Distribution segment distributes generic and certain select brand pharmaceutical products manufactured by third parties, as well as by the company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians offices. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. Watson Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Parsippany, New Jersey.
52 Week High
10/16/12 - $89.90
52 Week Low
01/24/12 - $55.00
Average Volume 10 Days
WPI Does Not Pay Dividends
Watson Pharmaceuticals, Inc. confirmed that U.S. District Court for the District of Columbia has granted summary judgment in favor of Watson and ordered the U.S. Food and Drug Administration (FDA) to approve Watson's generic version of Actos(R) (Pioglitazone Hydrochloride 15 mg, 30 mg and 45 mg tablets). Watson plans to begin shipping the product immediately upon receipt of final FDA approval. On August 15, 2012, Watson announced that it had filed suit against the FDA challenging the Agency's decision regarding Watson's entitlement to shared exclusivity for its generic version of Actos(R) (Pioglitazone Hydrochloride 15 mg, 30 mg and 45 mg tablets).
Watson Pharmaceuticals, Inc. announced that its subsidiary Watson Laboratories, Inc-Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Trospium Chloride Extended-release Capsules, the generic equivalent to Allergan's Sanctura XR(R). Watson intends to begin shipping the product immediately. Sanctura XR(R) is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. For the 12 months ending July 31, 2012, Sanctura XR(R) had total U.S. sales of approximately $67 million according to IMS Health data.
Watson Pharmaceuticals, Inc. announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application (ANDA) for Irbesartan Tablets USP, 75 mg, 150 mg and 300 mg, the generic equivalent to Sanofi's Avapro(R). Watson intends to begin shipping the product immediately. Avapro(R) is indicated for the treatment of hypertension when used alone or in combination with other antihypertensive agents. It is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. For the 12 months ending August 31, 2012, Avapro(R) and its generic equivalents had total U.S. sales of approximately $390 million according to IMS Health data.
Market data is delayed at least 15 minutes.
Market data is delayed at least 15 minutes.
|Forest Laboratories Inc||$34.62 USD||+0.41|
|Life Technologies Corp||$48.62 USD||+0.78|
|Mylan Inc/PA||$25.00 USD||+1.06|
|Perrigo Co||$117.37 USD||+0.22|
|UCB SA||€44.32 EUR||+0.155|
|No related news found for this Watson Pharmaceuticals Inc.|
|Upgrade Today||citamar||2012-10-16 12:10:17|
|Lidoderm Settlement- Big News||thoughful14||2012-10-16 12:10:13|
|Downgrade today||jimbollini||2012-10-16 12:10:04|
|News-- Adderall||thoughful14||2012-10-16 12:09:59|
|Deal Update||thoughful14||2012-10-16 12:09:54|
|GS addes WPI to Conviction buy list $87||getintoh20||2012-10-16 12:09:50|
|where are the retail investors?||spwangsu||2012-10-16 12:09:44|
|Significant article||thoughful14||2012-10-16 12:09:40|
|After I read I bought teva p/e 8||babajon5babajon5||2012-10-16 12:09:34|
|Watson 2Q2012 Non-GAAP Diluted EPS Increases 41% to $1.42; Net Revenue Increases 25%||bluecheese4u||2012-10-16 12:09:30|
|what the hell?||zeppelinman2567||2012-10-16 12:09:22|
|So, When's the Split?||buffumjr18||2012-10-16 12:09:15|
|All on board!||oim1257||2012-10-16 12:09:11|
|New all time high close||thoughful14||2012-10-16 12:09:07|
|Is the FDA picking winners and losers...||congress502000||2012-10-16 12:09:00|
|Profit Taking||citamar||2012-10-16 12:08:56|
|MAJOR NEWS||thoughful14||2012-10-16 12:08:50|
|WPI ready for short pain patch||infoanalysis||2012-10-16 12:08:45|
|Stock Split||citamar||2012-10-16 12:08:33|
|Is Watson Pharmaceuticals, Inc about to plunge? I think I have figured it out||emmabosserman||2012-10-16 12:08:26|
|Watson should buy TARO Pharmaceuticals?||imho_dyodd||2012-10-16 12:08:14|
|Going for second jump||oim1257||2012-10-16 12:08:09|
|Does Watson want to consider Impax IPXL under $30 before big Parkinson Approval? Remake o...||cobbob46||2012-10-16 12:07:56|
|Also researched and see compliance and qaulity control execs left WPI and went to Impax. ...||cobbob46||2012-10-16 12:07:51|
Get our Stock Market & Financial Investment news alerts in your inbox